**Core Concept:**
Long acting dopamine agonists are a class of medications that mimic the effects of dopamine, a neurotransmitter involved in regulating movement, cognition, and mood. Dopamine agonists are used in the treatment of Parkinson's disease, a disorder characterized by motor symptoms such as tremors, rigidity, and bradykinesia, as well as non-motor symptoms like cognitive decline and mood disorders.

**Why the Correct Answer is Right:**
The correct answer is D. Rotigotine, a long-acting dopamine agonist, is a selective non-ergoline dopamine agonist that mimics the effects of dopamine by binding to dopamine D1 and D3 receptors. Unlike short acting dopamine agonists, rotigotine has a more constant release profile, ensuring a stable dopamine level in the brain. This constant release profile makes rotigotine suitable for long-term treatment of Parkinson's disease, providing sustained symptomatic relief while minimizing "on-off" fluctuations.

**Why Each Wrong Option is Incorrect:**
A. Pramipexole is a dopamine agonist that binds to both D1 and D2 receptors, but its release profile is not as constant as rotigotine. It is primarily used for the treatment of Parkinson's disease and restless leg syndrome.
B. Apomorphine is a short-acting dopamine agonist that binds to D1, D2, and D3 receptors. It is administered subcutaneously via an implantable pump, making it suitable for patients who have motor fluctuations due to Parkinson's disease. However, it is not long-acting.
C. Apomorphine is not a dopamine agonist, but a dopamine receptor agonist, binding to D1, D2, and D3 receptors. It is a short-acting medication, administered subcutaneously via an implantable pump, making it suitable for patients with motor fluctuations due to Parkinson's disease but not for long-term management.
D. Rotigotine is a long-acting dopamine agonist that binds to D1 and D3 receptors. Its constant release profile makes it suitable for long-term management of Parkinson's disease, minimizing "on-off" fluctuations.

**Clinical Pearl:**
Rotigotine transdermal system is an example of a long-acting dopamine agonist used in the management of Parkinson's disease. It is an effective alternative to levodopa, the first-line treatment for Parkinson's disease, as it helps to reduce motor fluctuations and "on-off" phenomenon. The rotigotine transdermal system provides a constant release of dopamine, thereby ensuring sustained symptomatic relief and minimizing the risk of motor fluctuations.